uterine myoma
Conditions
Interventions
MRI during the growth phase (7th day to 10th day of menstruation). Measure the size (volume) of uterine myoma. Oral administration of cabergolin for 16 weeks (Oral administration of cabergolin oral ad
Sponsors
Shiga University of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients who are hospitalized or hospitalized at Obstetrics and Gynecology Department, Shiga Medical University Hospital during this research period (2) Women admitting menstruation (3) having uterine myoma (4) There is hope for treatment (5) With regard to participation in this research, those who obtained consent by signing the consent form by the principal
Exclusion criteria
Exclusion criteria: (1) A person with severe anemia (hemoglobin concentration is 8 g/dl or less) (2) Those who have been confirmed from medical records or inquiries that allergies and severe side effects, which are thought to be attributable to research drugs, have developed (occurred) in the past (3) Persons who are menopause at the beginning of registration (4) Pregnant women and lactating women at the beginning of registration (5) Other patients whose research responsibility / sharers judged inappropriate as subjects of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare myoma volume using MRI | — |
Countries
Japan
Contacts
Public ContactAsuka higuchi
Shiga University of Medicine Obstetrics and gynecology science course
Outcome results
None listed